PrimeRFP SCOUT · Federal Contract Recompete Brief

W81K0025PA252Transarterial radioembolization USING — Boston Scientific Corp

Boston Scientific Corp holds $69.8M across 5,464 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 5 related awards in the incumbent pipeline. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Sep 30, 2026 PoP end — agencies typically plan 12–18 months ahead.

W40m Mrc0 West

Awarding office

Boston Scientific Corp

Recipient

Sep 30, 2026

PoP end

$553K

Obligated

$553K

Potential

325412

NAICS

6515

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Boston Scientific Corp — $90

Contract facts

NONE

Contract numberW81K0025PA252

AgencyW40m Mrc0 West

Awarding officeW40m Mrc0 West

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentBoston Scientific Corp

CAGE1FKE6

UEIYWDHHW3DLNQ1

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6515

Place of performanceJBSA FT SAM HOUSTON TX

Pricing typeFirm Fixed Price

Extent competedNot Competed Under SAP

PoP startOct 1, 2025

PoP end (current)Sep 30, 2026

Obligated$553K

Current value$553K

Potential value$553K

TRANSARTERIAL RADIOEMBOLIZATION USING YTTRIUM-90 MICROSPHERES IS A THERAPEUTIC OPTION FOR PATIENTS WITH INTERMEDIATE-OR ADVANCED-STAGE HEPATOCELLULAR CARCINOMA, INCLUDING THOSE WITH RECURRENT OR INOPERABLE HEPATOCELLULAR CARCINOMA. is a federal NONE award for W40m Mrc0 West held by Boston Scientific Corp. Estimated value $553K ($553K obligated). Current period of performance ends Sep 30, 2026. Last award drew 1 bidder. Place of performance: JBSA FT SAM HOUSTON TX.

Recompete timing

Public

● Expiring in 40 days

Current PoP ends Sep 30, 2026 (40 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Boston Scientific Corp — $69.8M obligated across 5,464 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($69.8M) · all agencies

Department of Defense (DOD)$40.6M · 58%Department of Veterans Affairs (VA)$29.3M · 42%

Related awards

Same incumbent

36C26126N0005

VAPAHCS THERASPHERE Y90 RADIOPHARMACEUTICALS

$954K

Sep 30, 2026

36C26126F0019

THERASPHERE YTTIRUM-90 (Y-90) GLASS

$834K

Sep 30, 2026

36C26226N0239

THERASPHERE Y-90

$693K

Sep 30, 2026

36C26226N0070

THERASPHERE Y-90

$397K

Sep 30, 2026

36C26225N0045

THERASPHERE Y-90

$275K

Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract W81K0025PA252?

W81K0025PA252 (Transarterial radioembolization USING) is a W40m Mrc0 West award with a potential value of $553K, currently held by Boston Scientific Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded W81K0025PA252?

W40m Mrc0 West awarded W81K0025PA252 to Boston Scientific Corp (potential $553K).

Who is the incumbent on W81K0025PA252?

Boston Scientific Corp is the incumbent with $69.8M across 5464 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.

When does Boston Scientific Corp’s W81K0025PA252 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jul 2, 2026 · refreshed monthlyLatest procurement action Dec 22, 2025